Skip to Main content Skip to Navigation
New interface
Journal articles

Apixaban to Prevent Venous Thromboembolism in Patients with Cancer

Abstract : Patients with active cancer have an increased risk of venous thromboembolism, which results in substantial morbidity, mortality, and health care expenditures. The Khorana score (range, 0 to 6, with higher scores indicating a higher risk of venous thromboembolism) has been validated to identify patients with cancer at elevated risk for this complication and may help select those who could benefit from thromboprophylaxis.
Complete list of metadata
Contributor : Ghislaine Calvez Connect in order to contact the contributor
Submitted on : Thursday, February 28, 2019 - 2:43:05 PM
Last modification on : Thursday, March 31, 2022 - 11:00:02 AM

Links full text




Marc Carrier, Karim Abou-Nassar, Ranjeeta Mallick, Vicky Tagalakis, Sudeep Shivakumar, et al.. Apixaban to Prevent Venous Thromboembolism in Patients with Cancer. New England Journal of Medicine, 2019, 380 (8), pp.711-719. ⟨10.1056/NEJMoa1814468⟩. ⟨hal-02052475⟩



Record views